← Leaderboards
Ronald S. Veazey
Tulane University Of Louisiana
$44,796,137
Attributed
$45,198,810
Total exposure
133
Grants
100
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$45,198,810 · 133
By mechanism
R01$18,516,168 · 7
U19$9,830,895 · 4
P51$8,663,389 · 112
N01$4,796,693 · 2
P30$1,500,694 · 2
P60$1,156,350 · 1
Top collaborators
- Marcelo J Kuroda1 shared
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Mario Tomas Philipp$11,469,177
Others in their field
Top investigators on “Macaca”
- Barton F Haynes · Duke University$291,402,363
- Peter Gordon Gillespie · Oregon Health And Science University$96,229,141
- Richard A Gibbs · Baylor College Of Medicine$82,807,896
- Dennis R. Burton · Scripps Research Institute$75,153,374
- Larry S. Schlesinger · Texas Biomedical Research Institute$72,536,876
- Dan H. Barouch · Fred Hutchinson Cancer Center$68,546,715
Research focus
MacacaResourcesGrantUnited States National Institutes Of HealthFundingVirusMacaca MulattaTransmission ProcessSourceResearch PersonnelInfectionVaginaPrimatesPreventHiv InfectionsInstitutionCellsMicrobicideComputer Retrieval Of Information On Scientific Projects DatabaseAnimalsMucous MembraneViralHiv-1Simian Human Immunodeficiency Virus
Grant awards (200)
Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection$828,935
R01 · FY2024 · AI · contact PI
Evaluation of the Immunogenicity and Efficacy of HIV-1 SOSIP Envelope Protein Vaccine Delivered with or without Recombinant Viral Vector Vaccines$676,780
N01 · FY2024 · AI · contact PI
Evaluation of the Immunogenicity and Efficacy of HIV-1 SOSIP Envelope Protein Vaccine Delivered with or without Recombinant Viral Vector Vaccines$1,110,234
N01 · FY2023 · AI · contact PI
Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection$834,697
R01 · FY2023 · AI · contact PI
Non-Human Primate Core$212,740
P30 · FY2023 · AI · contact PI
Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection$823,420
R01 · FY2022 · AI · contact PI
Non-Human Primate Core$258,306
P30 · FY2022 · AI · contact PI
Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection$821,586
R01 · FY2021 · AI · contact PI
Non-Human Primate Core$258,459
P30 · FY2021 · AI · contact PI
Evaluation of the Immunogenicity and Efficacy of HIV-1 SOSIP Envelope Protein Vaccine Delivered with or without Recombinant Viral Vector Vaccines$1,925,712
N01 · FY2020 · AI · contact PI
Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection$790,880
R01 · FY2020 · AI · contact PI
Testing novel microbicide candidates in sustained release formulations$653,749
R01 · FY2020 · AI · contact PI
Non-Human Primate Core$258,498
P30 · FY2020 · AI · contact PI
Elicitation of α4β7-Competitive Antibodies in Rhesus Macaques by a Synthetic V2 Immunogen$67,942
N01 · FY2020 · AI · contact PI
Testing novel microbicide candidates in sustained release formulations$643,131
R01 · FY2019 · AI · contact PI
Elicitation of α4β7-Competitive Antibodies in Rhesus Macaques by a Synthetic V2 Immunogen$410,241
N01 · FY2019 · AI · contact PI
Non-Human Primate Core$265,464
P30 · FY2019 · AI · contact PI
Scientific Unit: Division of Comparative Pathology Office of the Chair$85,293
P51 · FY2019 · OD · contact PI
Testing novel microbicide candidates in sustained release formulations$644,378
R01 · FY2018 · AI · contact PI
Scientific Unit: Division of Comparative Pathology Office of the Chair$85,293
P51 · FY2018 · OD · contact PI
Role of Macrophages in Lung Disease Pathogenesis of Pediatric AIDS$805,346
R01 · FY2017 · HL · contact PI
Testing novel microbicide candidates in sustained release formulations$663,342
R01 · FY2017 · AI · contact PI
Elicitation of α4β7-Competitive Antibodies in Rhesus Macaques by a Synthetic V2 Immunogen$303,353
N01 · FY2017 · AI · contact PI
Nonhuman Primate Core$247,227
P30 · FY2016 · AI · contact PI
P187 - MULTIPLY EXPOSED VAGINALLY, UNINFECTED MACAQUE MODEL$245,277
N01 · FY2015 · AI · contact PI
Research Component 1$220,965
P60 · FY2014 · AA · contact PI
P187 - MULTIPLY EXPOSED VAGINALLY, UNINFECTED MACAQUE MODEL$57,154
N01 · FY2014 · AI · contact PI
Early Events in Mucosal SIV Pathogenesis$700,169
R01 · FY2013 · AI · contact PI
Research Component 1$222,534
P60 · FY2013 · AA · contact PI
Early Events in Mucosal SIV Pathogenesis$744,861
R01 · FY2012 · AI · contact PI
Testing practical microbicides in macaques$286,787
U19 · FY2012 · AI · contact PI
Research Component 1$221,651
P60 · FY2012 · AA · contact PI
Early Events in Mucosal SIV Pathogenesis$816,065
R01 · FY2011 · AI · contact PI
Testing practical microbicides in macaques$658,957
U19 · FY2011 · AI · contact PI
Research Component 1$237,372
P60 · FY2011 · AA · contact PI
MODELING HIV-1 PRIMARY TRANSMISSION$57,750
P51 · FY2011 · RR · contact PI
INHIBITORS OF HIV-DENDRITIC CELL INTERACTIONS AS MICROBICIDES$57,750
P51 · FY2011 · RR · contact PI
INTERSUBTYPE RECOMBINANTS FOR POLYVALENT ANTI-HIV VACCINE$57,750
P51 · FY2011 · RR · contact PI
SYNDECAN AGONISTS AND ANTAGONISTS AS MICROBICIDES$57,750
P51 · FY2011 · RR · contact PI
EFFECTS OF HIV-1 IN MALE RHESUS MACAQUE MODEL$57,750
P51 · FY2011 · RR · contact PI
IMPORTANCE OF ANTIBODIES IN HIV PREVENTION AND VACCINATION$57,750
P51 · FY2011 · RR · contact PI
EARLY EVENTS IN MUCOSAL SIV PATHOGENESIS$57,750
P51 · FY2011 · RR · contact PI
ROLE OF NON-NEUTRALIZING ANTIBODIES IN PROTECTION FROM HIV$57,750
P51 · FY2011 · RR · contact PI
COMBINING MICROBICIDES AND VACCINES TO PREVENT HIV TRANSMISSION$57,750
P51 · FY2011 · RR · contact PI
TESTING MARAVIROC AS A MICROBICIDE$57,750
P51 · FY2011 · RR · contact PI
IMPORTANCE OF ANTIBODY ISOTYPE IN VAGINAL HIV TRANSMISSION$57,750
P51 · FY2011 · RR · contact PI
AN SIRNA-BASED MICROBICIDE TO PREVENT HIV TRANSMISSION$57,750
P51 · FY2011 · RR · contact PI
EARLY EVENTS IN VAGINAL SHIV AND SIV TRANSMISSION$57,750
P51 · FY2011 · RR · contact PI
EVALUATING MUCOSAL IMMUNE RESPONSES IN THE VAGINA$57,750
P51 · FY2011 · RR · contact PI
EVALUATION OF RANTES ANALOGUES FOR PROTECTION FROM SHIV$57,750
P51 · FY2011 · RR · contact PI
THE EFFECTS OF ALCOHOL ON SIV PATHOGENESIS$57,750
P51 · FY2011 · RR · contact PI
PATHOGENESIS OF NEONATAL SIV INFECTION$57,750
P51 · FY2011 · RR · contact PI
EVALUATION OF FUSION INHIBITORS AS MICROBICIDES FOR SHIV$57,750
P51 · FY2011 · RR · contact PI
EFFECTS OF CIRCUMCISION ON HIV TRANSMISSION$45,135
P51 · FY2011 · RR · contact PI
MOLECULAR PATHOLOGY CORE$37,186
P51 · FY2011 · RR · contact PI
Early Events in Mucosal SIV Pathogenesis$824,281
R01 · FY2010 · AI · contact PI
Testing practical microbicides in macaques$783,535
U19 · FY2010 · AI · contact PI
Comparative gynecology of Humans and Macaques$584,442
U19 · FY2010 · AI · contact PI
Research Component 1$253,828
P60 · FY2010 · AA · contact PI
NHP Symposium on AIDS - New Orleans$73,089
R13 · FY2010 · RR · contact PI
IMPORTANCE OF ANTIBODY ISOTYPE IN VAGINAL HIV TRANSMISSION$61,801
P51 · FY2010 · RR · contact PI
EARLY EVENTS IN VAGINAL SHIV AND SIV TRANSMISSION$61,801
P51 · FY2010 · RR · contact PI
EVALUATING MUCOSAL IMMUNE RESPONSES IN THE VAGINA$61,801
P51 · FY2010 · RR · contact PI
EVALUATION OF RANTES ANALOGUES FOR PROTECTION FROM SHIV$61,801
P51 · FY2010 · RR · contact PI
MECHANISMS OF CD4 DEPLETION AND PROLIFERATION IN SIV$61,801
P51 · FY2010 · RR · contact PI
THE EFFECTS OF ALCOHOL ON SIV PATHOGENESIS$61,801
P51 · FY2010 · RR · contact PI
PATHOGENESIS OF NEONATAL SIV INFECTION$61,801
P51 · FY2010 · RR · contact PI
EVALUATION OF FUSION INHIBITORS AS MICROBICIDES FOR SHIV$61,801
P51 · FY2010 · RR · contact PI
AN SIRNA-BASED MICROBICIDE TO PREVENT HIV TRANSMISSION$61,801
P51 · FY2010 · RR · contact PI
IMPORTANCE OF ANTIBODIES IN HIV PREVENTION AND VACCINATION$61,801
P51 · FY2010 · RR · contact PI
EARLY EVENTS IN MUCOSAL SIV PATHOGENESIS$61,801
P51 · FY2010 · RR · contact PI
ROLE OF NON-NEUTRALIZING ANTIBODIES IN PROTECTION FROM HIV$61,801
P51 · FY2010 · RR · contact PI
COMBINING MICROBICIDES AND VACCINES TO PREVENT HIV TRANSMISSION$61,801
P51 · FY2010 · RR · contact PI
TESTING MARAVIROC AS A MICROBICIDE$61,801
P51 · FY2010 · RR · contact PI
MOLECULAR PATHOLOGY CORE$61,801
P51 · FY2010 · RR · contact PI
Early Events in Mucosal SIV Pathogenesis$827,743
R01 · FY2009 · AI · contact PI
Macaque studies$721,628
U19 · FY2009 · AI · contact PI
Testing practical microbicides in macaques$652,256
U19 · FY2009 · AI · contact PI
Comparative gynecology of Humans and Macaques$572,068
U19 · FY2009 · AI · contact PI
ROLE OF NON-NEUTRALIZING ANTIBODIES IN PROTECTION FROM HIV$62,691
P51 · FY2009 · RR · contact PI
IMPORTANCE OF ANTIBODY ISOTYPE IN VAGINAL HIV TRANSMISSION$62,691
P51 · FY2009 · RR · contact PI
AN SIRNA-BASED MICROBICIDE TO PREVENT HIV TRANSMISSION$62,691
P51 · FY2009 · RR · contact PI
EARLY EVENTS IN VAGINAL SHIV AND SIV TRANSMISSION$62,691
P51 · FY2009 · RR · contact PI
EVALUATING MUCOSAL IMMUNE RESPONSES IN THE VAGINA$62,691
P51 · FY2009 · RR · contact PI
EVALUATION OF RANTES ANALOGUES FOR PROTECTION FROM SHIV$62,691
P51 · FY2009 · RR · contact PI
MECHANISMS OF CD4 DEPLETION AND PROLIFERATION IN SIV$62,691
P51 · FY2009 · RR · contact PI
THE EFFECTS OF ALCOHOL ON SIV PATHOGENESIS$62,691
P51 · FY2009 · RR · contact PI
EMERGENCE OF CYTOTOXIC T CELLS IN SIV INFECTION$62,691
P51 · FY2009 · RR · contact PI
PATHOGENESIS OF NEONATAL SIV INFECTION$62,691
P51 · FY2009 · RR · contact PI
EVALUATION OF FUSION INHIBITORS AS MICROBICIDES FOR SHIV$62,691
P51 · FY2009 · RR · contact PI
TESTING MARAVIROC AS A MICROBICIDE$62,691
P51 · FY2009 · RR · contact PI
COMBINING MICROBICIDES AND VACCINES TO PREVENT HIV TRANSMISSION$62,691
P51 · FY2009 · RR · contact PI
MOLECULAR PATHOLOGY CORE$60,106
P51 · FY2009 · RR · contact PI
Testing practical microbicides in macaques$1,017,895
U19 · FY2008 · AI · contact PI
Macaque studies$658,139
U19 · FY2008 · AI · contact PI
Comparative gynecology of Humans and Macaques$573,571
U19 · FY2008 · AI · contact PI
Pathogenesis of Neonatal SIV Infection$383,693
R01 · FY2008 · AI · contact PI
PATHOGENESIS OF NEONATAL SIV INFECTION$64,630
P51 · FY2008 · RR · contact PI
EVALUATION OF FUSION INHIBITORS AS MICROBICIDES FOR SHIV$64,630
P51 · FY2008 · RR · contact PI
EMERGENCE OF CYTOTOXIC T CELLS IN SIV INFECTION$64,630
P51 · FY2008 · RR · contact PI
THE EFFECTS OF ALCOHOL ON SIV PATHOGENESIS$64,630
P51 · FY2008 · RR · contact PI
MECHANISMS OF CD4 DEPLETION AND PROLIFERATION IN SIV$64,630
P51 · FY2008 · RR · contact PI
EVALUATION OF RANTES ANALOGUES FOR PROTECTION FROM SHIV$64,630
P51 · FY2008 · RR · contact PI
EVALUATING MUCOSAL IMMUNE RESPONSES IN THE VAGINA$64,630
P51 · FY2008 · RR · contact PI
CELL MEDIATED IMUNE RESPONSES IN SHIV162-P INFECTED MACAQUES$64,630
P51 · FY2008 · RR · contact PI
EARLY EVENTS IN VAGINAL SHIV AND SIV TRANSMISSION$64,630
P51 · FY2008 · RR · contact PI
AN SIRNA-BASED MICROBICIDE TO PREVENT HIV TRANSMISSION$64,630
P51 · FY2008 · RR · contact PI
IMPORTANCE OF ANTIBODY ISOTYPE IN VAGINAL HIV TRANSMISSION$64,630
P51 · FY2008 · RR · contact PI
Macaque studies$592,941
U19 · FY2007 · AI · contact PI
Evaluation of AFE Inhibitors for Protection from SHIV Vaginal Challenge$542,487
U19 · FY2007 · AI · contact PI
Pathogenesis of Neonatal SIV Infection$391,124
R01 · FY2007 · AI · contact PI
The Effect Alcohol on SIV Pathogenesis$360,342
R01 · FY2007 · AA · contact PI
AN SIRNA-BASED MICROBICIDE TO PREVENT HIV TRANSMISSION$71,639
P51 · FY2007 · RR · contact PI
PATHOGENESIS OF NEONATAL SIV INFECTION$71,638
P51 · FY2007 · RR · contact PI
EVALUATING MUCOSAL IMMUNE RESPONSES IN THE VAGINA$71,638
P51 · FY2007 · RR · contact PI
EVALUATION OF RANTES ANALOGUES FOR PROTECTION FROM SHIV$71,638
P51 · FY2007 · RR · contact PI
MECHANISMS OF CD4 DEPLETION AND PROLIFERATION IN SIV$71,638
P51 · FY2007 · RR · contact PI
THE EFFECTS OF ALCOHOL ON SIV PATHOGENESIS$71,638
P51 · FY2007 · RR · contact PI
EMERGENCE OF SIV-SPECIFIC CYTOTOXIC T CELLS IN SIV INFECTION$71,638
P51 · FY2007 · RR · contact PI
EVALUATION OF FUSION INHIBITORS AS TREATMENT FOR HIV$71,638
P51 · FY2007 · RR · contact PI
CELL MEDIATED IMUNE RESPONSES IN SHIV162-P INFECTED MACAQUES$71,638
P51 · FY2007 · RR · contact PI
EARLY EVENTS IN VAGINAL SHIV AND SIV TRANSMISSION$71,638
P51 · FY2007 · RR · contact PI
EVALUATION OF FUSION INHIBITORS AS MICROBICIDES FOR SHIV$71,621
P51 · FY2007 · RR · contact PI
EVALUATION OF AFE INHIBITORS FOR PROTECTION FROM SHIV VAGINAL CHALLENG$612,233
U19 · FY2006 · AI · contact PI
Macaque studies$546,829
U19 · FY2006 · AI · contact PI
The Effect Alcohol on SIV Pathogenesis$530,787
R01 · FY2006 · AA · contact PI
Pathogenesis of Neonatal SIV Infection$402,806
R01 · FY2006 · AI · contact PI
Mechanisms of CD4 Depletion and Proliferation in SIV$216,757
R01 · FY2006 · AI · contact PI
EMERGENCE OF SIV-SPECIFIC CYTOTOXIC T CELLS IN SIV INFECTION$65,435
P51 · FY2006 · RR · contact PI
EARLY EVENTS IN VAGINAL SHIV AND SIV TRANSMISSION$65,435
P51 · FY2006 · RR · contact PI
CELL MEDIATED IMUNE RESPONSES IN SHIV162-P INFECTED MACAQUES$65,435
P51 · FY2006 · RR · contact PI
COINCIDENT AIDS/RELAPSING MALARIA$65,435
P51 · FY2006 · RR · contact PI
EVALUATION OF FUSION INHIBITORS AS TREATMENT FOR HIV$65,435
P51 · FY2006 · RR · contact PI
EVALUATING MUCOSAL IMMUNE RESPONSES IN THE VAGINA$65,435
P51 · FY2006 · RR · contact PI
EVALUATION OF RANTES ANALOGUES FOR PROTECTION FROM SHIV$65,435
P51 · FY2006 · RR · contact PI
MECHANISMS OF CD4 DEPLETION AND PROLIFERATION IN SIV$65,435
P51 · FY2006 · RR · contact PI
THE EFFECTS OF ALCOHOL ON SIV PATHOGENESIS$65,435
P51 · FY2006 · RR · contact PI
PATHOGENESIS OF NEONATAL SIV INFECTION$65,435
P51 · FY2006 · RR · contact PI
EVALUATION OF FUSION INHIBITORS AS MICROBICIDES FOR SHIV$65,435
P51 · FY2006 · RR · contact PI
EVALUATION OF AFE INHIBITORS FOR PROTECTION FROM SHIV VAGINAL CHALLENG$1,027,127
U19 · FY2005 · AI
The Effect Alcohol on SIV Pathogenesis$554,773
R01 · FY2005 · AA
Pathogenesis of Neonatal SIV Infection$412,500
R01 · FY2005 · AI
Mechanisms of CD4 Depletion and Proliferation in SIV$400,000
R01 · FY2005 · AI
EVALUATING MUCOSAL IMMUNE RESPONSES IN THE VAGINA$56,171
P51 · FY2005 · RR
EVALUATION OF A REVERSE-TRANSCRIPTASE SHIV IN RHESUS MACAQUES$56,171
P51 · FY2005 · RR
CELL MEDIATED IMUNE RESPONSES IN SHIV162-P INFECTED MACAQUES$56,171
P51 · FY2005 · RR
PATHOGENESIS OF SIV IN NATURAL AFRICAN MONKEY HOSTS$56,171
P51 · FY2005 · RR
EVALUATION OF FUSION INHIBITORS AS TREATMENT FOR HIV$56,171
P51 · FY2005 · RR
PATHOGENESIS OF NEONATAL SIV INFECTION$54,500
P51 · FY2005 · RR
EVALUATION OF FUSION INHIBITORS AS MICROBICIDES FOR SHIV$54,500
P51 · FY2005 · RR
EVALUATION OF RANTES ANALOGUES FOR PROTECTION FROM SHIV$54,500
P51 · FY2005 · RR
MECHANISMS OF CD4 DEPLETION AND PROLIFERATION IN SIV$54,500
P51 · FY2005 · RR
THE EFFECTS OF ALCOHOL ON SIV PATHOGENESIS$54,500
P51 · FY2005 · RR
EMERGENCE OF SIV-SPECIFIC CYTOTOXIC T CELLS IN SIV INFECTION$54,500
P51 · FY2005 · RR
EVALUATING TRANSIENT ANTIRETROVIRAL THERAPY AS A VACCINE FOR SIV INFECTION$52,511
P51 · FY2005 · RR
The Effect Alcohol on SIV Pathogenesis$581,722
R01 · FY2004 · AA
Pathogenesis of Neonatal SIV Infection$412,500
R01 · FY2004 · AI
Mechanisms of CD4 Depletion and Proliferation in SIV$400,000
R01 · FY2004 · AI
EVALUATION OF FUSION INHIBITORS AS MICROBICIDES FOR SHIV$47,161
P51 · FY2004 · RR
PATHOGENESIS OF SIV IN NATURAL AFRICAN MONKEY HOSTS$47,161
P51 · FY2004 · RR
EVALUATION OF FUSION INHIBITORS AS TREATMENT FOR HIV$47,161
P51 · FY2004 · RR
A REVERSE-TRANSCRIPTASE SHIV IN RHESUS MACAQUES$47,161
P51 · FY2004 · RR
EVALUATING MUCOSAL IMMUNE RESPONSES IN THE VAGINA$47,161
P51 · FY2004 · RR
POST-INOCULATION ANTIRETROVIRAL THERAPY: VACCINE FOR SIV$47,161
P51 · FY2004 · RR
EVALUATION OF RANTES ANALOGUES FOR PROTECTION FROM SHIV$47,161
P51 · FY2004 · RR
MECHANISMS OF CD4 DEPLETION AND PROLIFERATION IN SIV$47,161
P51 · FY2004 · RR
THE EFFECTS OF ALCOHOL ON SIV PATHOGENESIS$47,161
P51 · FY2004 · RR
SIV-SPECIFIC CYTOTOXIC T CELLS IN SIV INFECTION$47,161
P51 · FY2004 · RR
ONTOGENY OF THE NEONATAL MACAQUE IMMUNE SYSTEM$47,161
P51 · FY2004 · RR
The Effect Alcohol on SIV Pathogenesis$554,215
R01 · FY2003 · AA
Mechanisms of CD4 Depletion and Proliferation in SIV$355,049
R01 · FY2003 · AI
EVALUATION OF FUSION INHIBITORS AS MICROBICIDES FOR SHIV$61,560
P51 · FY2003 · RR
EMERGENCE OF SIV-SPECIFIC CYTOTOXIC T CELLS IN SIV INFECTION$61,544
P51 · FY2003 · RR
EVALUATING MUCOSAL IMMUNE RESPONSES IN THE VAGINA$61,544
P51 · FY2003 · RR
THE EFFECTS OF ALCOHOL ON SIV PATHOGENESIS$61,544
P51 · FY2003 · RR
TRANSIENT POST-INOCULATION ANTIRETROVIRAL THERAPY AS A VACCINE FOR SIV$61,544
P51 · FY2003 · RR
EVALUATION OF FUSION INHIBITORS AS TREATMENT FOR HIV$61,544
P51 · FY2003 · RR
EVALUATION OF A REVERSE-TRANSCRIPTASE SHIV IN RHESUS MACAQUES$61,544
P51 · FY2003 · RR
ONTOGENY OF THE NEONATAL MACAQUE IMMUNE SYSTEM$61,544
P51 · FY2003 · RR
MECHANISMS OF CD4 DEPLETION AND PROLIFERATION IN SIV$61,544
P51 · FY2003 · RR
EVALUATION OF RANTES ANALOGUES FOR PROTECTION FROM SHIV$61,544
P51 · FY2003 · RR
Mechanisms of CD4 Depletion and Proliferation in SIV$442,426
R01 · FY2002 · AI
High-speed cell sorter$427,553
S10 · FY2002 · RR
The Effect Alcohol on SIV Pathogenesis$283,392
R01 · FY2002 · AA
PHYSIOLOGIC CHARACTERISTICS OF MACAQUE INTESTINE FOLLOWING INFECTION W/ SIV$111,112
P51 · FY2002 · RR
EARLY EFFECTS OF SIV INFECTION ON GUT ASSOCIATED LYMPHOID TISSUES$111,112
P51 · FY2002 · RR
ASSESS CELL CYCLE KINETICS IN NON HUMAN PRIMATE TISSUES$111,112
P51 · FY2002 · RR
KINETICS OF IMMUNOLOGIC RECONSTITUTION OF GALT FOLLOWING HAART$111,112
P51 · FY2002 · RR
"MEMORY" CD4+ T CELLS ARE RAPIDLY ELIMINATED IN SIV INFECTION IN VIVO$111,112
P51 · FY2002 · RR
PRIMARY SIV INFECTION IS MUCOSAL DISEASE$111,112
P51 · FY2002 · RR
PROGESTERONE IMPLANTS ENHANCE SIV VAGINAL TRANSMISSION &EARLY VIRUS LOAD$111,112
P51 · FY2002 · RR
Mechanisms of CD4 Depletion and Proliferation in SIV$11,499
R01 · FY2002 · AI
Evaluation of inhibitors for protection from HIV/SIV$0
P01 · FY2002 · AI
Evaluation of inhibitors for protection from HIV/SIV$0
P01 · FY2002 · AI
Evaluation of Novel Chemokine Analogues$0
P01 · FY2002 · AI
Mechanisms of CD4 Depletion and Proliferation in SIV$400,000
R01 · FY2001 · AI
ONTOGENY OF THE NEONATAL MACAQUE IMMUNE SYSTEM$118,718
R29 · FY2001 · HD
PHYSIOLOGIC CHARACTERISTICS OF MACAQUE INTESTINE FOLLOWING INFECTION W/ SIV$111,112
P51 · FY2001 · RR
PROGESTERONE IMPLANTS ENHANCE SIV VAGINAL TRANSMISSION &EARLY VIRUS LOAD$111,112
P51 · FY2001 · RR
PRIMARY SIV INFECTION IS MUCOSAL DISEASE$111,112
P51 · FY2001 · RR